The role of cyclosporin in prolonging survival in vascularized bone allografts.
It is known that experimental vascularized bone allografts are subject to host rejection. To be useful clinically, this rejection response would need to be controlled. Cyclosporin is a potent immunosuppressant whose precise role in vascularized bone allograft transplantation has not been established. Using a proven reliable vascularized knee allograft model in inbred rats, cyclosporin was used postoperatively both continuously and short term (14 days after transplant) at 10 mg/kg per day as recipient treatment. Across a strong histocompatibility barrier, continuous cyclosporin was required for long-term graft survival. Short-term therapy delayed rejection for 4 to 6 weeks. However, across a weak histocompatibility barrier, short-term therapy was as effective as continuous therapy in achieving long-term graft survival. The implication is that a limited course of cyclosporin may be clinically successful in sustaining vascularized bone allograft survival, provided the genetic disparity between graft and host has been minimized by genetic matching techniques.
Paskert
J P
JP
Yaremchuk
M J
MJ
Randolph
M A
MA
Weiland
A J
AJ
D000818:Animals; D016025:Bone Transplantation; D001842:Bone and Bones / Q000098:blood supply; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D007717:Knee; D051381:Rats; D011919:Rats, Inbred Strains; D014184:Transplantation, Homologous
D003524:Cyclosporins